Cabozantinib-related cardiotoxicity

a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients

Roberto Iacovelli, Chiara Ciccarese, Giuseppe Fornarini, Francesco Massari, Davide Bimbatti, Claudia Mosillo, Sara Elena Rebuzzi, Vincenzo Di Nunno, Massimiliano Grassi, Emanuela Fantinel, Andrea Ardizzoni, Giampaolo Tortora

Research output: Contribution to journalArticle

Abstract

Aims: Data regarding the cardiac toxicity of cabozantinib lacks. The aim of our study was to assess the risk of cabozantinib-related cardiotoxicity in mRCC patients. Methods: We performed a multicentre prospective study on mRCC patients treated with cabozantinib between October 2016 and November 2017. Transthoracic echocardiogram and plasma biomarkers assay were assessed at baseline, 3 and 6 months after cabozantinib initiation. Results: The study population included 22 mRCC patients. At baseline, 9.1% had a reduced left ventricular ejection fraction (LVEF), but none had a left ventricular systolic dysfunction. Patients with baseline reduced LVEF did not show further significant LVEF modification after 3 months. After 6 months, only 1 had an LVEF decline >10% compared to baseline, resulting in LV systolic dysfunction. At baseline, 64.7% and 27.3% of patients had elevated precursor brain natriuretic peptide (proBNP) and high-sensitivity troponin I (hsTnI), respectively. Among patients with basal normal proBNP and hsTnI, none had elevated values at 3 and 6 months. No correlation was found between basal elevated proBNP and basal reduced LVEF (P =.29), and between elevated proBNP and reduced LVEF after 6 months (P =.37). Similarly, we found no correlations between elevated hsTnI and reduced LVEF or elevated proBNP at baseline (P =.47; P =.38), at 3 (P =.059; P =.45) and after 6 months (P =.72; P = 1.0). Conclusions: This prospective study revealed a modest risk of developing left ventricular systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time-points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.

Original languageEnglish
JournalBritish Journal of Clinical Pharmacology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Renal Cell Carcinoma
Stroke Volume
Brain Natriuretic Peptide
Troponin I
Left Ventricular Dysfunction
Biomarkers
Prospective Studies
Cardiotoxicity
cabozantinib
Multicenter Studies
Population

Keywords

  • cabozantinib
  • cardiotoxicity
  • high-sensitivity troponin I
  • metastatic renal cell carcinoma
  • precursor brain natriuretic peptide

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cabozantinib-related cardiotoxicity : a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. / Iacovelli, Roberto; Ciccarese, Chiara; Fornarini, Giuseppe; Massari, Francesco; Bimbatti, Davide; Mosillo, Claudia; Rebuzzi, Sara Elena; Di Nunno, Vincenzo; Grassi, Massimiliano; Fantinel, Emanuela; Ardizzoni, Andrea; Tortora, Giampaolo.

In: British Journal of Clinical Pharmacology, 01.01.2019.

Research output: Contribution to journalArticle

Iacovelli, Roberto ; Ciccarese, Chiara ; Fornarini, Giuseppe ; Massari, Francesco ; Bimbatti, Davide ; Mosillo, Claudia ; Rebuzzi, Sara Elena ; Di Nunno, Vincenzo ; Grassi, Massimiliano ; Fantinel, Emanuela ; Ardizzoni, Andrea ; Tortora, Giampaolo. / Cabozantinib-related cardiotoxicity : a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. In: British Journal of Clinical Pharmacology. 2019.
@article{9b251dd2642d41f0b610e760ef91b0bd,
title = "Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients",
abstract = "Aims: Data regarding the cardiac toxicity of cabozantinib lacks. The aim of our study was to assess the risk of cabozantinib-related cardiotoxicity in mRCC patients. Methods: We performed a multicentre prospective study on mRCC patients treated with cabozantinib between October 2016 and November 2017. Transthoracic echocardiogram and plasma biomarkers assay were assessed at baseline, 3 and 6 months after cabozantinib initiation. Results: The study population included 22 mRCC patients. At baseline, 9.1{\%} had a reduced left ventricular ejection fraction (LVEF), but none had a left ventricular systolic dysfunction. Patients with baseline reduced LVEF did not show further significant LVEF modification after 3 months. After 6 months, only 1 had an LVEF decline >10{\%} compared to baseline, resulting in LV systolic dysfunction. At baseline, 64.7{\%} and 27.3{\%} of patients had elevated precursor brain natriuretic peptide (proBNP) and high-sensitivity troponin I (hsTnI), respectively. Among patients with basal normal proBNP and hsTnI, none had elevated values at 3 and 6 months. No correlation was found between basal elevated proBNP and basal reduced LVEF (P =.29), and between elevated proBNP and reduced LVEF after 6 months (P =.37). Similarly, we found no correlations between elevated hsTnI and reduced LVEF or elevated proBNP at baseline (P =.47; P =.38), at 3 (P =.059; P =.45) and after 6 months (P =.72; P = 1.0). Conclusions: This prospective study revealed a modest risk of developing left ventricular systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time-points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.",
keywords = "cabozantinib, cardiotoxicity, high-sensitivity troponin I, metastatic renal cell carcinoma, precursor brain natriuretic peptide",
author = "Roberto Iacovelli and Chiara Ciccarese and Giuseppe Fornarini and Francesco Massari and Davide Bimbatti and Claudia Mosillo and Rebuzzi, {Sara Elena} and {Di Nunno}, Vincenzo and Massimiliano Grassi and Emanuela Fantinel and Andrea Ardizzoni and Giampaolo Tortora",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bcp.13895",
language = "English",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cabozantinib-related cardiotoxicity

T2 - a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients

AU - Iacovelli, Roberto

AU - Ciccarese, Chiara

AU - Fornarini, Giuseppe

AU - Massari, Francesco

AU - Bimbatti, Davide

AU - Mosillo, Claudia

AU - Rebuzzi, Sara Elena

AU - Di Nunno, Vincenzo

AU - Grassi, Massimiliano

AU - Fantinel, Emanuela

AU - Ardizzoni, Andrea

AU - Tortora, Giampaolo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aims: Data regarding the cardiac toxicity of cabozantinib lacks. The aim of our study was to assess the risk of cabozantinib-related cardiotoxicity in mRCC patients. Methods: We performed a multicentre prospective study on mRCC patients treated with cabozantinib between October 2016 and November 2017. Transthoracic echocardiogram and plasma biomarkers assay were assessed at baseline, 3 and 6 months after cabozantinib initiation. Results: The study population included 22 mRCC patients. At baseline, 9.1% had a reduced left ventricular ejection fraction (LVEF), but none had a left ventricular systolic dysfunction. Patients with baseline reduced LVEF did not show further significant LVEF modification after 3 months. After 6 months, only 1 had an LVEF decline >10% compared to baseline, resulting in LV systolic dysfunction. At baseline, 64.7% and 27.3% of patients had elevated precursor brain natriuretic peptide (proBNP) and high-sensitivity troponin I (hsTnI), respectively. Among patients with basal normal proBNP and hsTnI, none had elevated values at 3 and 6 months. No correlation was found between basal elevated proBNP and basal reduced LVEF (P =.29), and between elevated proBNP and reduced LVEF after 6 months (P =.37). Similarly, we found no correlations between elevated hsTnI and reduced LVEF or elevated proBNP at baseline (P =.47; P =.38), at 3 (P =.059; P =.45) and after 6 months (P =.72; P = 1.0). Conclusions: This prospective study revealed a modest risk of developing left ventricular systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time-points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.

AB - Aims: Data regarding the cardiac toxicity of cabozantinib lacks. The aim of our study was to assess the risk of cabozantinib-related cardiotoxicity in mRCC patients. Methods: We performed a multicentre prospective study on mRCC patients treated with cabozantinib between October 2016 and November 2017. Transthoracic echocardiogram and plasma biomarkers assay were assessed at baseline, 3 and 6 months after cabozantinib initiation. Results: The study population included 22 mRCC patients. At baseline, 9.1% had a reduced left ventricular ejection fraction (LVEF), but none had a left ventricular systolic dysfunction. Patients with baseline reduced LVEF did not show further significant LVEF modification after 3 months. After 6 months, only 1 had an LVEF decline >10% compared to baseline, resulting in LV systolic dysfunction. At baseline, 64.7% and 27.3% of patients had elevated precursor brain natriuretic peptide (proBNP) and high-sensitivity troponin I (hsTnI), respectively. Among patients with basal normal proBNP and hsTnI, none had elevated values at 3 and 6 months. No correlation was found between basal elevated proBNP and basal reduced LVEF (P =.29), and between elevated proBNP and reduced LVEF after 6 months (P =.37). Similarly, we found no correlations between elevated hsTnI and reduced LVEF or elevated proBNP at baseline (P =.47; P =.38), at 3 (P =.059; P =.45) and after 6 months (P =.72; P = 1.0). Conclusions: This prospective study revealed a modest risk of developing left ventricular systolic dysfunction related to cabozantinib. A lack of correlation between elevated cardiac biomarkers and reduced LVEF at different time-points was detected. Assessments of the cardiac function should be reserved at the occurrence of clinical symptoms.

KW - cabozantinib

KW - cardiotoxicity

KW - high-sensitivity troponin I

KW - metastatic renal cell carcinoma

KW - precursor brain natriuretic peptide

UR - http://www.scopus.com/inward/record.url?scp=85063628938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063628938&partnerID=8YFLogxK

U2 - 10.1111/bcp.13895

DO - 10.1111/bcp.13895

M3 - Article

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

ER -